Our study, according to the scientific literature, indicates that GnRH-a treatment may lead to an increase in BMI, especially in children with CPP who have a normal weight at the start of treatment, although the overall effect on the progression of obesity is minimal. The gene discussed is GNRH1; the disease is obesity due to melanocortin 4 receptor deficiency.